F9 embryocarcinoma cells: A cell autonomous model to study the functional selectivity of RARs and RXRs in retinoid signaling

Histology and Histopathology

Volumn 16, Issue 3, 2001, Pages 909-922

  Rochette Egly, C ^a   Chambon, P ^a  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Agonist; Antagonist; Endodermal differentiation; F9 EC cells; Gene Knock out; Heterodimers; Phosphorylation; Retinoid receptors

Indexed keywords

CYCLIC AMP; MEMBRANE RECEPTOR; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID; RETINOID X RECEPTOR;

AMINO ACID SEQUENCE; APOPTOSIS; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL MUTANT; CELL PROLIFERATION; CULTURE MEDIUM; DIMERIZATION; DNA RESPONSIVE ELEMENT; EMBRYONAL CARCINOMA; ENDODERM; GENE ACTIVATION; GENE EXPRESSION; GENETIC RECOMBINATION; GENETIC TRANSCRIPTION; IN VITRO STUDY; KNOCKOUT GENE; LIGAND BINDING; METABOLIC ACTIVATION; MOLECULAR BIOLOGY; NONHUMAN; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; RECEPTOR SENSITIVITY; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; BINDING SITES; CARCINOMA, EMBRYONAL; CELL DIFFERENTIATION; CELL DIVISION; DNA, NEOPLASM; GENETIC ENGINEERING; MICE; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; RETINOIDS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRETINOIN; TUMOR CELLS, CULTURED;

MAMMALIA;

EID: 0034924237     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Hyperphosphorylation of the retinoid X receptor alpha (RXRα) by activated c-Jun N-terminal Kinases (JNKs)
2. Enhancement of HL-60 differentiation by a new class of retinoids with selective affinity on retinoid X receptor
3. TFIIH interacts with the retinoic acid receptor γ and phosphorylates its AF-1 activating domain through cdk7
4. Retinoic acid receptor/retinoid X receptor heterodimers can be activated through both subunits providing a basis for synergistic transactivation and cellular differentiation
5. Crystal structure of the ligand-binding domain of the human nuclear receptor RXRα
6. Loss of retinoic acid receptor gamma function in F9 cells by gene disruption results in aberrant Hoxa-1 expression and differentiation upon retinoic acid treatment
7. Targeted disruption of retinoic acid receptor alpha (RARα) and RAR gamma results in receptor-specific alterations in retinoic acid-mediated differentiation and retinoic acid metabolism
8. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation
9. The retinoid signaling pathway: Molecular and genetic analyses
10. A decade of molecular biology of retinoic acid receptors
11. Two distinct actions of retinoid-receptor ligands
12. Distinct retinoid X receptor-retinoic acid receptor heterodimers are differentially involved in the control of expression of retinoid target genes in F9 embryonal carcinoma cells
13. Specific and redundant functions of retinoid X receptor/retinoic acid receptor heterodimers in differentiation, proliferation, and apoptosis of F9 embryonal carcinoma cells
14. RXRα-null F9 embryonal carcinoma cells are resistant to the differentiation, anti-proliferative and apoptotic effects of retinoids
15. Dominant negative mutant of retinoic acid receptor alpha inhibits retinoic acid-induced P19 cell differentiation by binding to DNA
16. Functional inhibition of retinoic acid response by dominant negative retinoic acid receptor mutants
17. Identification of a retinoic acid element in the retinoic acid receptor beta gene
18. Activation function 2 (AF-2) of retinoic acid receptor and 9-cis retinoic acid receptor: Presence of a conserved autonomous constitutive activating domain and influence of the nature of the response element on AF-2 activity
19. Crystal structure of the human RXRalpha ligand-binding domain to its natural ligand: 9-cis retinoic acid
20. The targeted disruption of both alleles of RARbeta(2) in F9 cells results in the loss of retinoic acid-associated growth arrest
21. The retinoic acid receptor-β2 contains two separate cell specific transactivation domain, at the N-terminus and in the ligand-binding domain
22. Transcription factor IIH: A key player in the cellular response to DNA damage
23. Organization and regulation of mitogen-activated protein kinase signaling pathways
24. Immunodetection of multiple species of retinoic acid receptor alpha: Evidence for phosphorylation
25. Orphan nuclear receptors: From gene to function
26. Differential recognition of target genes by nuclear receptors monomers, dimers and heterodimers
27. The coregulator exchange in transcriptional functions of nuclear receptors
28. Cellular biology and biochemistry of the retinoids
29. F9 teratocarcinoma cells as a model for the differentiation of parietal and visceral endoderm in the mouse embryo
30. Cyclic AMP analogs and retinoic acid influence the expression of retinoic acid receptor alpha, beta, and gamma mRNAs in F9 teratocarcinoma cells
31. Nonsteroid nuclear receptors: What are genetic studies telling us about their role in real life?
32. Genetic evidence that the retinoid signal is transduced by heterodimeric RXR/RAR functional units during mouse development
33. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
34. Dimerization with RXRs and phosphorylation modulate the retinoic acid- induced degradation of RARα and RARγ through the ubiquitin-proteasome pathway
35. Retinoic acid is potent growth activator of mouse primordial germ cells in vitro
36. Retinoic acid resistance of the variant embryonal carcinoma cell line RAC65 is caused by expression of a trauncated RARα
37. Stress pathway induces phosphorylation of retinoid X receptor
38. Multiplicity generates diversity in the retinoic acid signalling pathways
39. Skin abnormalities generated by temporally controlled RXRα mutations in mouse epidermis
40. The RXR heterodimers and orphan receptors
41. The nuclear receptor superfamily: The second decade
42. The RXRα ligand-dependent activation function 2 (AF-2) is important for mouse development
43. Retinoid X receptor (RXR) within the RXR-retinoic acid receptor heterodimer binds its ligand and enhances retinoid-dependent gene expression
44. Proteasome-mediated degradation of transcriptional activators correlates with activation domain potency in vivo
45. The nuclear receptor ligand-binding domain: Structure and function
46. Cyclin-dependent kinases: Engines, clocks, and microprocessors
47. RARs and RXRs: Evidence for two autonomous transactivation functions (AF-1 and AF-2) and heterodimerization in vivo
48. Promoter context- and response element-dependent specificity of the transcriptional activation and modulating functions of retinoic acid receptors
49. The conserved amphipatic alpha-helical core motif of RARγ and RARα activating domains is indispensable for RA-induced differentiation of F9 cells
50. A dominant negative mutation of the alpha retinoic acid receptor gene in a retinoic acid-nonresponsive embryonal carcinoma cell
51. Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid
52. Stimulation of RARα activation function AF-1 through binding to the general transcription factor TFIIH and phosphorylation by CDK7
53. Retinoic acid receptor-β: Immunodetection and phosphorylation on tyrosine residues
54. Retinoic acid receptor γ: Specific immunodetection and phosphorylation
55. Phosphorylation of the retinoic acid receptor-α by protein kinase A
56. The AF-1 and AF-2 activating domains of retinoic acid receptor-α (RARα) and their phosphorylation are differentially involved in parietal endodermal differentiation of F9 cells and retinoid-induced expression of target genes
57. Synergistic activation of retinoic acid (RA)-responsive genes and induction of embryonal carcinoma cell differentiation by an RA receptor alpha (RARα)-RARβ-, or RARγ-selective ligand in combination with a retinoid X receptor-specific ligand
58. Mitogen-activated protein kinases: Specific messages from ubiquitous messengers
59. Activation and repression by nuclear hormone receptors: Hormone modulates an equilibrium between active and repressive states
60. Mouse teratocarcinoma cells: Prospects for the study of embryogenesis and neoplasia
61. The induction of differentiation in teratocarcinoma cells by retinoic acid
62. Hormonal induction of differentiation in teratocarcinoma stem cells: Generation of parietal endoderm by retinoic acid and dibutyryl cAMP
63. Reexpression of retinoic acid receptor (RAR)γ or overexpression of RARα or RARβ in RARγ-null F9 cells reveals a partial functional redundancy between the three RAR types
64. Cell-type and promoter-context dependent retinoic acid receptor (RAR) redundancies for RARβ2 and Hoxa-1 activation in F9 and P19 cells can be artefactually generated by gene knockouts
65. Phosphorylation of activation functions AF-1 and AF-2 of RARα and RARγ is indispensable for differentiation of F9 cells upon retinoic acid and cAMP treatment
66. Transcriptional regulation: Kamikaze activators
67. A mutation mimicking ligand-induced conformational change yields a constitutive RXR that senses allosteric effects in heterodimers
68. The expression of retinoid X receptor genes is regulated by all-trans- and 9-cis-retinoic acid in F9 teratocarcinoma cells
69. Thrombomodulin gene regulation by cAMP and retinoic acid in F9 embryonal carcinoma cells
70. Nuclear orphan receptors: The search for novel ligands and signaling pathways
71. A canonical structure for the ligand-binding domain of nuclear receptors
72. Cloning of murine alpha and beta retinoic acid receptors and a novel receptor gamma predominantly expressed in skin
73. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor α (RARα) and oncogenic RARα fusion proteins